News Image

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

Provided By GlobeNewswire

Last update: Aug 7, 2025

Second quarter performance driven by strong portfolio royalty revenue growth of 57%

2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million) and adjusted earnings per diluted share1 increased to $6.70 - $7.00 (previously $6.00 - $6.25)

Read more at globenewswire.com

LIGAND PHARMACEUTICALS

NASDAQ:LGND (10/17/2025, 8:25:24 PM)

After market: 181.65 0 (0%)

181.65

+0.88 (+0.49%)



Find more stocks in the Stock Screener

Follow ChartMill for more